Our Categories
Entrepreneurs
Tech
Talent
Energy
Oil & Gas
Mining
Health
Automotive
Aerospace
Finance & Fintech
Infrastructure
Sustainability
Professional Services
E-Commerce & Retail
Agribusiness & Food
Logistics
Mobility
Trade & Investment
Policy & Economy
Cybersecurity
AI, Cloud & Data
Chemicals
Multimedia
Podcast
Videos
Audio Articles
Opinion
Expert Contributor
Startup Contributor
Goverment
Embassy
Chamber of Commerce
Industry Association
Type
Spotlight
Entrepreneurs
Tech
Talent
Energy
Oil & Gas
Mining
Health
Automotive
Aerospace
Finance & Fintech
Infrastructure
Sustainability
Professional Services
E-Commerce & Retail
Agribusiness & Food
Logistics
Mobility
Trade & Investment
Policy & Economy
Cybersecurity
AI, Cloud & Data
Chemicals
Loading...
Loading...
Sector by:
Pfizer’s BRAFTOVI Regimen Approved for Metastatic CRC
By
MBN Staff
- Mon, 12/23/2024 - 13:39
Pfizer's BRAFTOVI, combined with cetuximab and mFOLFOX6, is FDA-approved for treating metastatic colorectal cancer with a BRAF V600E mutation.
Featured content
Most popular
Partnership Content
Sector by:
